Technology | Computer-Aided Detection Software | November 28, 2018

ScreenPoint Medical Receives FDA Clearance for Transpara Mammography AI Solution

Artificial intelligence application assists radiologists with reading screening mammograms, provides decision support

ScreenPoint Medical Receives FDA Clearance for Transpara Mammography AI Solution

November 28, 2018 — ScreenPoint Medical announced it has received 510(k) clearance from the U.S. Food & Drug Administration (FDA) for Transpara detection and decision support software, designed to assist radiologists with the reading of screening mammograms.

Transpara is the first FDA 510(k)-cleared artificial intelligence (AI) application for detecting breast cancer in screening mammograms, based on its functionality that interactively provides support for detection and diagnosis. The clearance was supported by the results of a multi-reader, multi-case reader study, which demonstrated that radiologists significantly improved detection accuracy when using Transpara for decision support without increasing reading times. In the study, the stand-alone sensitivity and specificity of Transpara was nearly at the same level as that of radiologists. The full results of the study, “Detection of breast cancer using mammography: Impact of an Artificial Intelligence support system,” were recently published in Radiology.1

In the editorial, “Will AI Succeed Where Traditional CAD Failed?”, published as a companion to the reader study, Manisha Bahl, M.D., wrote: “The results of the study by Rodríguez-Ruiz and colleagues suggest that integration of AI systems into routine clinical practice could help radiologists with varying levels of training and experience achieve performance benchmarks and therefore improve the quality of mammography across the country.”

Transpara already has European regulatory approval (CE Mark) for use with mammography and digital breast tomosynthesis (DBT) images from multiple vendors and is installed at leading breast imaging centers in Europe. Transpara DBT is still investigational in the U.S.

ScreenPoint will showcase Transpara and its integration with multiple vendor workstations at the 104th Annual Radiological Society of North America (RSNA) meeting, Nov. 25-30, 2018 in Chicago. Two studies demonstrating that radiologists significantly improved cancer detection in mammography when using Transpara while maintaining workflow will also be presented at RSNA:

  • “Detecting Breast Cancer in Mammography: A Deep Learning-Based Computer System versus 101 Radiologists”; and
  • “Improving Radiologists' Breast Cancer Detection with Mammography Using a Deep Learning-Based Computer System for Decision Support.”
     

Utilizing state-of-the-art image analysis and deep learning technology, Transpara automatically identifies soft-tissue and calcification lesions and combines the findings of all available views into a single cancer suspiciousness score. Breast imaging professionals can use this Transpara Score to automatically identify exams that are highly likely to be normal and the exams with features indicating highly increased risk of cancer. Interactive decision support is provided to improve assessment of lesions. Information is provided concurrent during reading and only when needed. As a result, it does not slow down reading.

For more information: www.screenpoint-medical.com

Reference

1. Rodriguez-Ruiz A., Krupinski E., Mordang J.J., et al. Detection of Breast Cancer with Mammography: Effect of an Artificial Intelligence Support System. Radiology, Nov. 20, 2018. https://doi.org/10.1148/radiol.2018181371

Related Content

Low-dose #CT #lung #scans are used to #screen for #lung_cancer in high-risk people such as heavy #smokers

Getty Images

News | Lung Imaging | April 16, 2021
April 17, 2021 — A deep learning algorithm accurately predicts the risk of death from...
#SiemensHealthineers #Varian #Siemens The transformative combination accelerates the company’s impact on #global #healthcare and establishes a strong partner for #customers and #patients along the entire #cancer care continuum and for many of the most threatening #diseases
News | Radiology Business | April 15, 2021
April 15, 2021 — Siemens Healthineers AG an
A doctor reading #CXR scans using #SenseCare-Chest #DR Pro #diagnostic #software.

A doctor reading CXR scans using SenseCare-Chest DR Pro diagnostic software.

News | Artificial Intelligence | April 14, 2021
April 14, 2021 — SenseTime, a world-leading...
Comparisons of high definition and standard definition infrared imaging for digital histopathology. Image courtesy of the Beckman Institute

Comparisons of high definition and standard definition infrared imaging for digital histopathology. Image courtesy of the Beckman Institute

News | Breast Imaging | April 14, 2021
April 14, 2021 — Detecting and analyzing breast cancer
The U.S. Food and Drug Administration (#FDA) authorized marketing of #Medtronic's #GIGenius, the first device that uses #artificialintelligence (#AI) based on #machinelearning to assist #clinicians in detecting #lesions (such as #polyps or suspected tumors) in the #colon in real time during a c#olonoscopy.

The GI Genius intelligent endoscopy module works in real-time, automatically identifying and marking (with a green box) abnormalities consistent with colorectal polyps, including small flat polyps.

News | Artificial Intelligence | April 12, 2021
A 37-year-old woman developed a new, palpable left supraclavicular lymphadenopathy lump five days after her first dose of the Moderna COVID-19 vaccine in the left arm. On the day of vaccination, the patient was asymptomatic. This is an example of how the vaccine can mimic cancer and swollen lymph nodes. Image used with permission of RSNA.

A 37-year-old woman developed a new, palpable left supraclavicular lymphadenopathy lump five days after her first dose of the Moderna COVID-19 vaccine in the left arm. On the day of vaccination, the patient was asymptomatic. This is an example of how the vaccine can mimic cancer and swollen lymph nodes. Read more about this case study. Image used with permission of RSNA.

Feature | Coronavirus (COVID-19) | April 09, 2021 | By Dave Fornell, Editor
While the mass COVID-19 vaccinat
3-D mammography reduces the number of breast cancer cases diagnosed in the period between routine screenings, when compared with traditional mammography, according to a large study from Lund University in Sweden. The results are published in the journal Radiology.

Getty Images

News | Breast Imaging | April 09, 2021
April 9, 2021 — 3-D mammography reduces the number of breast cancer cases diagnosed in the period between routine scr